These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491 [TBL] [Abstract][Full Text] [Related]
9. The genetic and molecular pathogenesis of NF1 and NF2. Yohay KH Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172 [TBL] [Abstract][Full Text] [Related]
10. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Angelo LS; Wu JY; Meng F; Sun M; Kopetz S; McCutcheon IE; Slopis JM; Kurzrock R Mol Cancer Ther; 2011 Nov; 10(11):2094-103. PubMed ID: 21903608 [TBL] [Abstract][Full Text] [Related]
11. The neurofibromatoses: when less is more. Gutmann DH Hum Mol Genet; 2001 Apr; 10(7):747-55. PubMed ID: 11257108 [TBL] [Abstract][Full Text] [Related]
12. Cell Fate following Irradiation of MDA-MB-231 and MCF-7 Breast Cancer Cells Pre-Exposed to the Tetrahydroisoquinoline Sulfamate Microtubule Disruptor STX3451. Hargrave SD; Joubert AM; Potter BVL; Dohle W; Marais S; Mercier AE Molecules; 2022 Jun; 27(12):. PubMed ID: 35744942 [TBL] [Abstract][Full Text] [Related]
13. The motor protein kinesin-1 links neurofibromin and merlin in a common cellular pathway of neurofibromatosis. Hakimi MA; Speicher DW; Shiekhattar R J Biol Chem; 2002 Oct; 277(40):36909-12. PubMed ID: 12191989 [TBL] [Abstract][Full Text] [Related]
14. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690 [TBL] [Abstract][Full Text] [Related]
15. NF2: the wizardry of merlin. Xiao GH; Chernoff J; Testa JR Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860 [TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterization of neurofibromatosis in southern Brazil. Rosset C; Vairo F; Cristina Bandeira I; Fonini M; Netto CBO; Ashton-Prolla P Expert Rev Mol Diagn; 2018 Jun; 18(6):577-586. PubMed ID: 29685074 [TBL] [Abstract][Full Text] [Related]
17. Progress toward the isolation and characterization of the genes causing neurofibromatosis. Menon AG; Gusella JF; Seizinger BR Brain Pathol; 1990 Sep; 1(1):33-40. PubMed ID: 1669691 [TBL] [Abstract][Full Text] [Related]
18. New insights into the neurofibromatoses. Gutmann DH Curr Opin Neurol; 1994 Apr; 7(2):166-71. PubMed ID: 8019663 [TBL] [Abstract][Full Text] [Related]